TABLE 3.
The results of the pairwise meta-analysis of change from baseline in trough FEV1.
| Group | Follow-up time | N | n | Heterogeneity | Model | MDs(ml) | 95%CIs | P |
|---|---|---|---|---|---|---|---|---|
| REV 22 vs PLA | 1 week | 1 | 37 vs. 56 | NA | NA | 53.40 | (45.79, 61.01) | <0.00001 |
| REV 44 vs PLA | 1 week | 1 | 32 vs. 56 | NA | NA | 55.00 | (46.70, 63.30) | <0.00001 |
| 4 weeks | 1 | 60 vs. 55 | NA | NA | 51.80 | (42.59, 61.01) | <0.00001 | |
| REV 88 vs PLA | 1 week | 1 | 35 vs 56 | NA | NA | 75.30 | (67.45, 83.15) | <0.00001 |
| 4 weeks | 1 | 63 vs. 55 | NA | NA | 187.40 | (178.35, 196.45) | <0.00001 | |
| 12 weeks | 1 | 161 vs. 146 | NA | NA | 79.22 | (75.72, 82.72) | <0.00001 | |
| 12 weeks | 1 | 152 vs. 150 | NA | NA | 160.50 | (156.27, 164.73) | <0.00001 | |
| REV 175 vs PLA | 1 week | 1 | 33 vs. 56 | NA | NA | 114.10 | (105.96, 122.24) | <0.00001 |
| 4 weeks | 1 | 59 vs. 55 | NA | NA | 166.60 | (157.33, 175.87) | <0.00001 | |
| 12 weeks | 2 | 310 vs. 296 | I 2 = 0%, p = 0.58 | Fixed | 146.91 | (144.20, 149.63) | <0.00001 | |
| REV 350 vs PLA | 1 week | 1 | 38 vs. 56 | NA | NA | 94.40 | (86.90, 101.90) | <0.00001 |
| 4 weeks | 1 | 63 vs. 55 | NA | NA | 170.60 | (161.59, 179.61) | <0.00001 | |
| REV 700 vs PLA | 1 week | 1 | 35 vs. 56 | NA | NA | 81.60 | (73.75, 89.45) | <0.00001 |
| REV 88 vs TIO | 4 weeks | 1 | 317 vs. 330 | NA | NA | -29.00 | (−30.82, −27.18) | <0.00001 |
| 13 weeks | 1 | 287 vs. 307 | NA | NA | -16.00 | (−17.96, −14.04) | <0.00001 | |
| 26 weeks | 1 | 239 vs. 283 | NA | NA | -14.80 | (−16.99, −12.61) | <0.00001 | |
| 39 weeks | 1 | 223 vs. 265 | NA | NA | -10.20 | (−12.51, −7.89) | <0.00001 | |
| 52 weeks | 1 | 212 vs. 248 | NA | NA | -42.70 | (−45.12, −40.28) | <0.00001 | |
| REV 175 vs TIO | 4 weeks | 2 | 371 vs. 420 | I 2 = 66%, p = 0.08 | Random | 13.51 | (8.32, 18.69) | <0.00001 |
| 13 weeks | 1 | 243 vs. 307 | NA | NA | 2.70 | (0.55, 4.85) | <0.00001 | |
| 26 weeks | 1 | 210 vs. 283 | NA | NA | 15.40 | (13.03, 17.77) | <0.00001 | |
| 39 weeks | 1 | 189 vs. 265 | NA | NA | -8.30 | (−10.85, −5.75) | <0.00001 | |
| 52 weeks | 1 | 185 vs. 248 | NA | NA | -39.20 | (−41.82, −36.58) | <0.00001 |
FEV1: Forced Expiratory Volume in 1 s; N: the number of included trials; n: the number of participants; MDs: mean differences; 95%CIs: 95% confidence intervals; REV 22: revefenacin 22 μg/day; REV 44: revefenacin 44 μg/day; REV 88: revefenacin 88 μg/day; REV 175: revefenacin 175 μg/day; REV 350: revefenacin 350 μg/day; REV 700: revefenacin 700 μg/day; PLA: placebo; TIO: tiotropium; Fixed: fixed-effects model; Random: random-effects model; NA: not applicable.